Thomas J. Liesegang, MD, received his medical degree from New York University and completed a medical internship at Duke University, followed by a residency at the Bascom Palmer Eye Institute. He then went on to complete a fellowship in external ocular disease and corneal surgery at Baylor College of Medicine in Houston, Texas.

Dr. Liesegang has taught and published extensively in the areas of corneal and external eye disease, with over 200 publications. In addition to serving as the Editor-in-Chief of the American Journal of Ophthalmology, he also serves as the Editor of the Transactions of the American Ophthalmological Society. He was previously the Abstract Editor of the AJO. He serves on the International Council of Ophthalmology's Task Force on Ophthalmology Continuing Education and on the Board of Directors of the Pan American Association of Ophthalmologists.

Dr. Liesegang has served as the American Academy of Ophthalmology's Senior Secretary for Clinical Education since 2001. Among other Academy positions Dr. Liesegang has held are: Secretary for Instruction from 1995 to 2000; Associate Secretary of the Ophthalmic Knowledge Assessment Program committee from 1991 to 1995; a member of the Preferred Practice Pattern committee; and a number of Task Forces and Liaison committees. He currently serves as Chair of the AAO's Ophthalmic Clinical Education Committee, Chair of the CME committee, and as a member of the EyeNet Advisory Board and the Committee on Aging.

Dr. Liesegang has practiced at the Mayo Clinic for 28 years, first in Rochester, Minnesota and later in Jacksonville, Florida where he is the Louis and Evelyn Krueger Professor in the Department of Ophthalmology.

Hans E. Grossniklaus, MD is the Calhoun Jr. Professor of Ophthalmology and Pathology, Director of the L.F. Montgomery Laboratory, and Vice Chairman of the Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia. He received a BA in chemistry and zoology from Miami University in 1976, MD from Ohio State University in 1980, and MBA from Emory University in 2006. He completed residencies in ophthalmology and pathology at Case Western Reserve University, in 1985 and 1988 and fellowships in ophthalmic pathology at the Wilmer Institute, Johns Hopkins University in 1985 and the Armed Forces Institute of Pathology in 1989. He has had over 20 visiting professorships. His areas of research interest are control of eye melanoma metastasis and pathobiology of choroidal neovascularization.

Dr. Grossniklaus is a recipient of the American Academy of Ophthalmology Senior Honor Award and Secretariat Award. He has also received the Heed Award, the W. R. Green Lecture Award, and the Research to Prevent Blindness Physician Scientist Award.

He currently serves on the editorial boards of five journals and is the past chair of the American Academy of Ophthalmology Basic and Clinical Science Course Section 4, Ophthalmic Pathology and Intraocular Tumors. He has over 300 publications in peer reviewed journals.

Gary N. Holland, MD is the Jack H. Skirball Professor of Ocular Inflammatory Diseases, and Chief of the Cornea-External Ocular Disease & Uveitis Division of the Department of Ophthalmology, David Geffen School of Medicine at UCLA, and is a member of the Jules Stein Eye Institute. He is also Director of the Ocular Inflammatory Disease Center, Jules Stein Eye Institute, and Director of the Institute's Clinical Research Center, which was created to provide support services for individuals engaged in patient-based research.

Dr. Holland grew up in southern California where he undertook much of his training. He obtained a Bachelor of Science degree in biological sciences at the University of California, Irvine (1975) and his medical degree at the UCLA School of Medicine, where he also completed his residency training in ophthalmology. He undertook fellowship training in both uveitis/external ocular diseases (Francis I. Proctor Foundation, University of California, San Francisco, 1983-1984) and corneal diseases and surgery (Emory University, 1984-1985). He returned to the UCLA Department of Ophthalmology as a faculty member in 1985.

Dr. Holland is especially interested in infectious diseases of the eye. In 1981, he was the first to describe the ophthalmic manifestations of AIDS. He has continued to be involved in the study of CMV retinitis and other AIDS-related ophthalmic problems. Dr. Holland also has a long-standing interest in ocular toxoplasmosis. He is currently working with investigators in Brazil, Europe, and the United States to understand the clinical features of ocular toxoplasmosis more thoroughly and to identify factors related to severity of disease. A third area of clinical and research interest is chronic anterior uveitis in children, as seen in those with juvenile idiopathic arthritis (JIA). He is currently investigating risk factors for development of vision-threatening complications in children with JIA-associated uveitis.

Since 1993, Dr. Holland has served as Associate Editor of the American Journal of Ophthalmology and is Co-Editor of the textbook, Ocular Infection & Immunity. He is a past President of the American Uveitis Society, and is a member of both the International Uveitis Study Group (IUSG) and of the International Ocular Inflammation Society (IOIS), serving on its International Council. In 2003, Dr. Holland was chosen to present the LX Edward Jackson Memorial Lecture "Ocular Toxoplasmosis: A global reassessment". He is Co-Editor of the textbook Ocular Infection & Immunity. In 2009, he was awarded the Jane Wyman Humanitarian Award by the Arthritis Foundation - Southern California Chapter, for his work on behalf of children with uveitis.

Research Support: National Eye Institute, Centers for Disease Control and Prevention.

Paul R. Lichter, MD, MS is the F. Bruce Fralick Professor of Ophthalmology and Visual Sciences and Chair of the University of Michigan's Department of Ophthalmology and Visual Sciences, a department founded in 1872. In addition, Lichter serves as Director of the University's W.K. Kellogg Eye Center. He is a native of Detroit and received his undergraduate, medical school, and ophthalmology residency education at the University of Michigan.

Dr. Lichter obtained his glaucoma fellowship training at the University of California, San Francisco, under the late Robert N. Shaffer, M.D.. Lichter's research and clinical interests involve glaucoma, clinical trials, genetics. and conflict of interest. Lichter has over 200 publications to his credit including scientific articles, editorials, and book chapters and has delivered over 30 named lectures, including the Edward Jackson Memorial Lecture in 1993.

Currently Dr. Lichter is Secretary-General of Academia Ophthalmologica Internationalis, a Director of The Heed Ophthalmic Foundation, and Chairman of the Society of Heed Fellows. He is a past Editor-in-Chief of the journal Ophthalmology. In 1996, Lichter served as the 100th President of the American Academy of Ophthalmology. He is also a Past President of the Association of University Professors of Ophthalmology, the American Ophthalmological Society, the Pan American Association of Ophthalmology, the Pan American Glaucoma Society, the Michigan Ophthalmological Society as well as a Past Chair of the American Board of Ophthalmology.

Richard K. Parrish II, MD, is Professor and Associate Dean for Graduate Medical Education at the University of Miami Miller School of Medicine in Miami, Florida. He also serves as Chairman of the Graduate Medical Education Committee and as the Designated Institutional Representative for the Jackson Health System/Jackson Memorial Hospital. Dr. Parrish earned his MD from the Indiana University School of Medicine, served his internship at the University of Alabama School of Medicine in Birmingham, and completed a residency at Willis Eye Hospital in Philadelphia, Pennsylvania. He finished a clinical and research glaucoma fellowship at Bascom Palmer Eye Institute/Anne Bates Leach Eye Hospital at the University of Miami Miller School of Medicine.

Dr Parrish is a member of the American Academy of Ophthalmology, the American Ophthalmological Society, and the Florida Ophthalmological Society. He has served as an Associate Editor for the Brief Reports section of the American Journal of Ophthalmology since 2002 and edited Bascom Palmer Eye Institute's Atlas of Ophthalmology. He edits the Transactions of the American Ophthalmological Society and serves as the American Glaucoma Society Councilor to the American Academy of Ophthalmology.

Dr Parrish is a Vice Chairman of Ocular Hypertension Treatment Study (OHTS) and Co-Principal Investigator of the OHTS Optic Disc Reading Center.

Consultant or Advisory Board: Alcon, Allergan, Pfizer, Alimera Sciences, Bausch & Lomb, Becton Dickinson Medical, Danube Pharmaceuticals, Glaukos, InnFocus, Merck, Othera Pharmaceuticals, Sirion Therapeutics, Vitreo Retinal Technologies

Anne Louise Coleman, MD, PhD is a Professor of Ophthalmology in the Jules Stein Eye Institute of the David Geffen School of Medicine at UCLA as well as Professor of Epidemiology in the UCLA School of Public Health. She holds the Frances and Ray Stark Endowed Chair at UCLA and is Director of the Jules Stein Eye Institute Mobile Eye Clinic. Currently she serves as the Senior Secretary for Quality of Care for the American Academy of Ophthalmology (AAO), and Annual Meeting Program Chair of the American Glaucoma Society.

Dr. Coleman received a BA in Chemistry from Duke University and an MD from the Medical College of Virginia, where she earned membership in the Alpha Omega Alpha honor society. After a surgical internship at the Medical College of Virginia, she went to the University of Illinois at Chicago for her residency training in ophthalmology, followed by fellowship training in glaucoma at the Wilmer Eye Institute, Johns Hopkins University. She received a PhD in Epidemiology from UCLA in 1997, where she earned membership in the Delta Omega honor society. She has received the AAO Senior Achievement Award (2004) and Secretariat Awards (2003, 2004).

Dr. Coleman's research is focused on the diagnosis, treatment, genetics, and societal impact of glaucoma, cataracts, and age-related macular degeneration (AMD), including the study of lifestyle limitations imposed on patients with these eye diseases. Ongoing research projects include participation as an investigator in the Ocular Hypertension Treatment Study; a population-based study of the prevalence of glaucoma and AMD in Thessaloniki, Greece; geographic variation in diagnostic procedures and clinical outcomes among patients with eye diseases in the Medicare population; and the possible association between hip fractures from falls and impaired vision from glaucoma, cataracts, and AMD.

With activities ranging from local to national and international organizations, Dr. Coleman has made numerous professional contributions. She is currently a consultant of the U.S. Food and Drug Administration Ophthalmic Devices Panel, and she chairs the Planning Committee of the National Eye Health Education Program of the National Institutes of Health. Since 2003, she has served as Executive Editor of Glaucoma for the American Journal of Ophthalmology

Consultant or Advisory Board: Alcon, Allergan, Pfizer, Science Based Health.

Janet L. Davis, MD, received a medical degree with high honors from Baylor College of Medicine in Houston, Texas, and completed a residency there in ophthalmology, where she was Chief Resident. She was a fellow in vitreoretinal diseases at Bascom Palmer Eye Institute, University of Miami Medical School and joined the National Eye Institute Laboratory of Immunology as a Senior Staff Fellow for two years under the mentorship of Dr. Robert Nussenblatt. She returned to Bascom Palmer Eye Institute and was promoted to Professor of Ophthalmology in 2000. In addition to a clinical practice in uveitis and ocular infections, she also sees patients with medical and surgical vitreoretinal disorders and conducts clinical research.

Dr. Davis's academic interests are infectious and inflammatory diseases of the eye, with an emphasis on diagnostic procedures and clinical management of uveitis, including the surgical management of uveitic complications. She is a member of the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Retina Society, Macula Society, American Society of Retina Specialists, American Uveitis Society (President, 2006 - 2008), the Pan-American Association of Ophthalmology, the International Uveitis Study Group, and the International Ocular Inflammation Society, for which she is a Council Representative for the United States. She became a Director of the American Board of Ophthalmology in 2006. She is a reviewer for several academic journals and an executive editor for the American Journal of Ophthalmology. By 2010, she had published 26 book chapters, 141 articles in peer-reviewed journals, and made numerous national and international presentations.

She has been recognized with the Senior Achievement Award of the American Academy of Ophthalmology, ARVO Silver Fellow, and listed in Best Doctors, America's Top Ophthalmologists, Florida Super Doctors, and Marquis Who's Who.

Consultant or Advisory Board: Centocor
Research Support: Novartis

Susan G. Elner, MD, is currently a Professor of Ophthalmology at the University of Michigan W. K. Kellogg Eye Center. She heads the uveitis service and her practice includes the treatment of vitreoretinal diseases. She is currently director of the vitreoretinal fellowship program at the University of Michigan.

She obtained her MD degree from the University of Chicago in 1982 and completed her ophthalmology residency at the same institution in 1986. Following a 2 year vitreoretinal fellowship with Dr Charles Schepens and the Retina Associates she joined the faculty at the University of Michigan in 1988.

She has served on the American Academy of Ophthalmology (AAO) Self-Assessment Committee from 1992-1998 and received an Achievement Award from the AAO in 2001. She has served as an ad hoc member of the Neurobiology C Merit Review Committee for the Department of Veterans Affairs from 2004-2008. She has recently served as a section editor for the journal, Eye. She has been elected as a member of the Retina Society and American Ophthalmologic Society (AOS). She recently completed a 3 year term on the Thesis Review Committee for the AOS, and served as the Committee chair during the final year.

Research Support: National Institutes of Health

Anselm Kampik, MD is Professor and Chairman of the Department of Ophthalmology, Ludwig Maximilians University Munich (LMU), Germany since 1993. From 1987 - 1993 he was Professor and Chairman at the Department of Ophthalmology, University of Würzburg, Germany. He received his medical degree from Ludwig Maximilians University, Munich Germany in 1975 and completed his residency in ophthalmology at the same institution 1979. He then went on to complete a fellowship in ophthalmic pathology at the Wilmer Institute, Johns Hopkins University in 1980, followed by a vitreoretinal fellowship in Germany and joined the faculty at the department of Ophthalmology of LMU, Munich. Besides ophthalmic pathology his main areas of research interests are vitreoretinal diseases, esp. diseases of the vitreoretinal interface, ocular cell biology and clinical research related to intraocular surgery. Dr. Kampik has taught and published extensively in his research fields, with over 350 publications in peer reviewed journals, and 13 books edited. In addition to serving as editorial board member of the American Journal of Ophthalmology, he also serves or served on numerous editorial boards including Der Ophthalmologe, Graefe's Archives, Investigative Ophthalmology and Visual Science, Retina, and European Journal of Ophthalmology. He currently also serves as Secretary-General of the Deutsche Ophthalmologische Gesellschaft (DOG), was president of DOG in 1997, and is amongst others member of the European Academy of Ophthalmology, the Club Jules Gonin, Euretina and the Macula Society. Since more than ten years he acts in the program committee of the German annual educational ophthalmology meeting "Augenärztliche Akademie Deutschland" (AAD).

Honoraria: Novartis
Research Support: Novartis, Thrombogenics, Alcon

John H. Kempen, MD, PhD is Director of the Ocular Inflammation Service and of Ophthalmic Epidemiology at the Scheie Eye Institute, Department of Ophthalmology, the University of Pennsylvania. He also serves as a Senior Scholar in the University of Pennsylvania Center for Clinical Epidemiology and Biostatistics.

Dr. Kempen received his undergraduate training at Stanford University, and completed his M.D. at the University of California, San Diego. His Ph.D. (Epidemiology), M.P.H. (International Health), and M.H.S. (Biostatistics) were completed at the Johns Hopkins University School of Hygiene and Public Health. He completed an internship at Santa Clara Valley Medical Center (San Jose, CA), residency in Ophthalmology at the University of Washington, and clinical fellowship in Uveitis and Clinical Immunology at the Wilmer Eye Institute. In addition, he completed research fellowships in Preventive Ophthalmology and Clinical Trials at Johns Hopkins.

Dr. Kempen is an ophthalmic epidemiologist, with particular interest in ocular inflammatory and infectious diseases. He has published extensively on ocular complications of AIDS, and directed the Johns Hopkins CMV Retinitis Cohort Study from 1998-2005, which characterized the effects of highly active antiretroviral therapy on the clinical course of cytomegalovirus retinitis. He conceived of, developed and currently chairs the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study, the first multicenter NIH-sponsored clinical research study in the field of ocular inflammatory diseases. He also serves as Vice-Chair of the Multicenter Uveitis Steroid Treatment (MUST) Trial, an investigator-initiated international clinical trial funded by the National Eye Institute. Completed work includes co-coordinating the Eye Diseases Prevalence Research Group. He is the founding Director of the Ocular Inflammation Service of the Scheie Eye Institute, which serves as a referral center for the management of ocular inflammatory diseases in Pennsylvania, New Jersey, Delaware, and adjacent states.

Consultant or Advisory Board: Lux Biosciences
Lectures: American Uveitis Society
Research Support: National Institutes of Health, Eyegate, Allergan, Cerimon, Enzo

Ian M. MacDonald MSc, MD CM is the Professor and Chair of the Department of Ophthalmology, University of Alberta, and Edmonton Zone Chief of the Ophthalmology Program of Alberta Health Services. From 2007-2008, he served for a two-year term as Branch Chief of Ophthalmic Genetics at the National Eye Institute of the National Institute of Health, Bethesda, Maryland. Dr. MacDonald completed residency training in Family Medicine at McGill University, Montreal, Ophthalmology residency training at the University of Ottawa, and Clinical Genetics fellowship training at the University of Ottawa, Queen's University, Kingston and the Hospital for Sick Children, Toronto. Dr. MacDonald is a member of the International Society for Genetic Eye Diseases & Retinoblastoma, the International Society for Clinical Electrophysiology and Vision. He has been a President of the Canadian Association of Pediatric Ophthalmologists, and a President of the Association Canadian University Professors of Ophthalmology. He is an Editor Emeritus for the Canadian Journal of Ophthalmology and currently serves on the Editorial Board of Survey of Ophthalmology for Genetics.

Dr. MacDonald has maintained continuous external grant funding throughout his career. Prior to becoming the Chair in Edmonton, in 1992, he was a Career Scientist of the Ontario Ministry of Health at the University of Ottawa. His areas of interest are inherited retinal disorders, in particular, maculopathies and choroideremia. In 2009, in recognition of his work in Canada to foster the development of academic Ophthalmology, he was elected to as a Fellow of the Canadian Academy of Health Sciences.

Research Support: Choroideremia Research Foundation, Canada; Foundation Fighting Blindness, Canada, Canadian Institutes for Health Research

Todd P. Margolis, MD, PhD received his B.S. from Stanford University in 1977. He subsequently received his PhD in Neuroscience and MD from UCSF in 1984. After internship in San Francisco, he trained as a resident in ophthalmology at UCSF with subseqeunt subspecialty training in corneal and external diseases at the F. I. Proctor Foundation. He then pursued postdoctoral research training on herpesvirus latency in the laboratory of Dr. Jack Stevens in the Department of Microbiology and Immunology at UCLA. While at UCLA he also served as a visiting assistant professor at the Jule Stein Eye Institute.

Dr. Margolis joined the faculty of the F. I. Proctor Foundation and the Department of Ophthalmology at UCSF as an Assistant professor in 1991. He was appointed Director of the F. I. Proctor Foundation and Professor of Ophthalmology in 1999. He is also Director of the Ralph and Sophie Heintz Research Laboratory. The primary focus of this lab is to carry out research on the cellular and molecular mechanisms that regulate the establishment and maintenance of latent neuronal infection with herpes simplex virus (HSV). Dr. Margolis' clinical expertise is in the diagnosis and management of infectious and inflammatory eye disease, with a particular interest in ocular disease due to the herpes viruses and ocular infections in immmune compromised hosts. His clinical research is aimed at understanding the pathogenic mechanisms leading to atypical presentations of ocular infections.

Advisor: National Eye Advisory Council
Research Support: National Institutes of Health, Littlefield Foundation, That Man May See.

Nancy J. Newman, MD is the Leo Delle Jolley Professor of Ophthalmology, Professor of Ophthalmology and Neurology and Instructor in Neurological Surgery at the Emory University School of Medicine, where she serves as the Director of Neuro-Ophthalmology. She also holds the academic position of Lecturer in Ophthalmology at the Harvard Medical School. She attended Princeton University, the University of London on a Marshall Scholarship, and Harvard Medical School. She trained in Neurology at the Massachusetts General Hospital and in Neuro-Ophthalmology at the Massachusetts Eye and Ear Infirmary. She is a Fellow of the American Academy of Neurology and of the North American Neuro-Ophthalmology Society.

She serves on the Editorial Boards of the American Journal of Ophthalmology, the Journal of the Neurological Sciences and the Journal of Neuro-Ophthalmology. She has over 300 publications, including scientific articles, book chapters and books, including the primary textbook in Neuro-Ophthalmology, Walsh & Hoyt's Clinical Neuro-Ophthalmology, 5th and 6th Editions. Her main research interests include disorders of the optic nerve and mitochondrial diseases. She also served on the Board of Trustees of Princeton University for 14 years and is currently a Princeton Trustee Emeritus.

Timothy W. Olsen, MD is the F. Phinizy Calhoun Sr. Professor of Ophthalmology and Chairman of the Department of Ophthalmology Director, Emory Eye Center in Atlanta Georgia. Dr. Olsen graduated from Medical School at the University of Kansas, completed his residency training at the University of Minnesota, and a Fellowship in Vitreoretinal Diseases and Surgery at Emory.

Dr. Olsen's research is funded through the National Institute on Aging (NIA) at the National Institutes of Health (NIH). He and key collaborators study the proteomics of Age related macular degeneration. Dr. Olsen also has collaborated with Mechanical Engineers on instrument design and prototype development. Dr. Olsen's other research has investigated specific methodology of drug delivery to posterior segment. Prior translational studies have investigated the use of small molecules in delaying retinal degeneration. While at the University of Minnesota, he was the director and founder of the Minnesota Lions Macular Degeneration Center.

Dr. Olsen is board certified by the American Board of Ophthalmology and the National Board of Medical Examiners. He serves on the executive committee for the Macula Society and holds membership in the Retina Society, the American Ophthalmologic Society (AOS), the Society of Heed Fellows, American Society of Retina Specialists (ASRS), American Academy of Ophthalmology (AAO), Association of University Professors in Ophthalmology (AUPO), the Association for Research in Vision and Ophthalmology (ARVO), and the Georgia Society of Ophthalmology (GSO). Within the AAO, Dr. Olsen chairs the Practicing Ophthalmologists Curriculum (POC) committee. He serves on the editorial board of the American Journal of Ophthalmology (AJO) and Investigative Ophthalmology and Visual Science (IOVS), and for Ocular Surgery News (OSN). Dr. Olsen enjoys teaching and has been awarded six distinguished teaching awards from four universities.

Patents: Regarding Scleral depressor, Treating visual disorder, and Surgical support structure.
Research Support: National Eye Institute, National Institutes of Health, Neurotech, iScience Interventional, Georgia Research Alliance

Randall J. Olson, MD, is the John A. Moran Presidential Professor and Chairman of the Department of Ophthalmology and Visual Sciences at the University of Utah School of Medicine. He is also the Chief Executive Officer of the John A. Moran Eye Center at the University of Utah. He received his MD degree from the University of Utah in 1973 and completed his residency at UCLA in 1977. He then completed two fellowships in cornea/external disease at the University of Florida and LSU.

Dr. Olson has, in particular, been involved with understanding complications and problems in association with cataract surgery, which is the most common surgical procedure in the United States today and represents a substantial part of an average ophthalmologist's practice. His key focus has been has been why intraocular lens designs are successful and how problems can be prevented. In assisting The David J. Apple Center for Biodevices Research and its predecessor, The Center for Intraocular Lens Research, at the University of Utah, many quality improvements and recalls of these lenses have occurred. Research in cataract removal technology has been another important interest. He publishes and lectures widely on these subjects.

Dr. Olson has been Chair of Ophthalmology and Visual Sciences at the University of Utah since June, 1979, when it was a one-person Division of Surgery. He has been the leader through the expansion into Departmental status and was involved in the fundraising and creation of the John A. Moran Eye Center dedicated in 1993. Due to continued expansion and size restriction, a second John A. Moran Eye Center was dedicated August 3, 2006 and represents 210,000 square feet, with over half the building dedicated to lab space involved in ophthalmic research.

Consultant or Advisory Board: AMO, Allergan, Becton Dickinson.
Equity Stock: Chakshu

Richard K. Parrish II, MD, is Professor and Associate Dean for Graduate Medical Education at the University of Miami Miller School of Medicine in Miami, Florida. He also serves as Chairman of the Graduate Medical Education Committee and as the Designated Institutional Representative for the Jackson Health System/Jackson Memorial Hospital. Dr. Parrish earned his MD from the Indiana University School of Medicine, served his internship at the University of Alabama School of Medicine in Birmingham, and completed a residency at Willis Eye Hospital in Philadelphia, Pennsylvania. He finished a clinical and research glaucoma fellowship at Bascom Palmer Eye Institute/Anne Bates Leach Eye Hospital at the University of Miami Miller School of Medicine.

Dr Parrish is a member of the American Academy of Ophthalmology, the American Ophthalmological Society, and the Florida Ophthalmological Society. He has served as an Associate Editor for the Brief Reports section of the American Journal of Ophthalmology since 2002 and edited Bascom Palmer Eye Institute's Atlas of Ophthalmology. He edits the Transactions of the American Ophthalmological Society and serves as the American Glaucoma Society Councilor to the American Academy of Ophthalmology.

Dr Parrish is a Vice Chairman of Ocular Hypertension Treatment Study (OHTS) and Co-Principal Investigator of the OHTS Optic Disc Reading Center.

Consultant or Advisory Board: Alcon, Allergan, Pfizer, Alimera Sciences, Bausch & Lomb, Becton Dickinson Medical, Danube Pharmaceuticals, Glaukos, InnFocus, Merck, Othera Pharmaceuticals, Sirion Therapeutics, Vitreo Retinal Technologies

Jay S. Pepose, MD, PhD is a subspecialist in refractive surgery, cornea and external diseases. He is Director of Pepose Vision Institute, Professor of Clinical Ophthalmology and Visual Sciences at Washington University and Director of the Midwest Cornea Foundation. Dr. Pepose earned his PhD in Microbiology/Immunology and MD at UCLA; completed residency training at The Wilmer Institute, The Johns Hopkins Hospital; and fellowship training at Georgetown University Medical Center. He is cited in America's Top Doctors and Best Doctors in America. Dr. Pepose is the recipient of the Cogan Award from ARVO and the Honor Award from the American Academy of Ophthalmology, and is a Fellow of ARVO and the American Academy of Ophthalmology.

He has received research support from both public and private sources, including the National Eye Institute. He has published extensively and lectured nationally and internationally on various aspects of refractive surgery, external diseases and eye banking, and is senior co-editor of the volume Ocular Infections and Immunity. He is currently involved in a number of clinical trials of presbyopia surgery, lens and laser based refractive surgery and diagnostic devices for detecting dry eye syndrome.

Consultant or Advisory Board: Tearlab, Acufocus.
Equity Stock Options: Acufocus

Julian D. Perry, MD received his medical degree from Columbia University College of Physicians and Surgeons in New York, NY, and completed his residency at Wills Eye Hospital in Philadelphia, PA. He completed a fellowship in neuro-ophthalmology at Wilmer Eye Institute in Baltimore, MD, and a fellowship in oculoplastic and orbital surgery at Jules Stein Eye Institute in Los Angeles, CA where he was a Heed Foundation AOS-Knapp Fellow.

He joined the Cleveland Clinic Foundation's Cole Eye Institute in 1999, where he limits his practice to ophthalmic plastic and reconstructive surgery. His specialty interests include aesthetic and reconstructive surgery of the eyelid, forehead and midface. His research interests include the study of new surgical techniques in oculofacial surgery and novel therapies for thyroid related orbitopathy. He has published over sixty peer-reviewed papers, two dozen book chapters, and he has co-edited a text on ocular oncology.

He is a member of the American Academy of Ophthalmology, and the American Society of Ophthalmic Plastic and Reconstructive Surgeons, Inc. He serves on the Editorial Board of Ophthalmic Plastic and Reconstructive Surgery and the American Journal of Ophthalmology. Dr. Perry has been recognized by the American Academy of Ophthalmology with an Achievement Award and is listed on Best Doctors in America. He is a three-time Cole Eye Institute Resident Teacher of the Year Award recipient. Dr. Perry precepts an American Society of Ophthalmic Plastic and Reconstructive Surgery Inc. approved fellowship in oculoplastic and orbital surgery.

M. Edward Wilson, Jr., MD was born and raised in Charleston, South Carolina. His MD degree is from the Medical University of South Carolina. After an internship and residency in ophthalmology at the National Naval Medical Center in Bethesda, Maryland, Dr. Wilson served a one-year fellowship in pediatric ophthalmology and strabismus with Dr. Marshall Parks.

Dr. Wilson is currently the Pierre G. Jenkins Professor and Chairman of the Department of Ophthalmology and the Director of the Albert Florens Storm Eye Institute at the Medical University of South Carolina in Charleston. Dr. Wilson has received a senior honor award from the American Association for Pediatric Ophthalmology and Strabismus and a senior achievement award from the American Academy of Ophthalmology. Dr. Wilson is a Past President and a past Statesmanship Award recipient of the Joint Commission on Allied Health Personnel in Ophthalmology and is Past Chairman of the American Academy of Ophthalmology's Basic and Clinical Science Course Committee responsible for Book 6 on Pediatric Ophthalmology and Strabismus.

Dr. Wilson is an Executive Editor of the American Journal of Ophthalmology and serves on the editorial board of the Journal of AAPOS. He served as Pediatric Issues Consultant to the National FDA Ophthalmic Devices Panel from 2003-2009. The South Carolina Society of Ophthalmology (SCSO) selected him for the inaugural Ophthalmologist-of-the-year Award in 2001. He currently serves on the SCSO Board of Directors. He is the immediate past president of his County Medical Society and is the current president of the Costenbader (Pediatric Ophthalmology) Society. He received the David Friendly Honor Award from the society in 2008. Dr. Wilson also serves on the CyberSight Board of Directors and is a member of the Cataract Working Group of the International Agency for the Prevention of Blindness. Dr. Wilson's research interests include surgical technique and IOL design for use in the treatment of pediatric cataracts, as well as the full range of strabismus in children and adults.

Dr. Wilson has given more than 500 invited presentations at national and international conferences including 12 named lectures. He has published over 200 scientific papers and has edited 2 books.

Elmer Y. Tu, MD is an Associate Professor of Clinical Ophthalmology and Director of the Cornea and External Disease Section of the Department of Ophthalmology and Visual Sciences, University of Illinois College of Medicine, Chicago, Illinois. He received a BS in Chemistry from the University of Miami in 1984 and an MD from the University of Miami School Of Medicine in 1988. He completed an ophthalmology residency at the University of Wisconsin, Madison in 1992 and a fellowship in Cornea and External Disease at the Bascom Palmer Eye Institute in 1993. He was formerly Director of the Corneal and External Disease Section, Department of Ophthalmology, University of Texas Health Science Center- San Antonio, San Antonio, Texas until 1999 and served as Residency Program Director for a portion of his time there. His area of research interest involves infectious and inflammatory diseases of the ocular surface and corneal surgery.

Dr. Tu is a recipient of the American Academy of Ophthalmology Honor Award and Secretariat Award. He was elected to the Alpha Omega Alpha Honor Society and is a consultant to the FDA Ophthalmic Devices Panel. He serves on the American Academy of Ophthalmology Basic and Clinical Science Course Cornea/External Disease Subcommittee, the AUPO Fellowship Compliance Committee and previously served on the Knowledge Base-Cornea/External Disease-Panel Subcommittee. He is also a member of the Board of Directors of the Cornea Society and a Past President of the Ocular Microbiology and Immunology Group. He is an Executive Editor for Cornea and External Diseases for the American Journal of Ophthalmology, and performs peer review on a regular basis for numerous national and international journals. He has also received numerous teaching awards and has been listed as a Best Doctor in America for over 10 years. In total, he has nearly 100 book chapters, peer-reviewed manuscripts, and abstracts in publication.

Tien Y. Wong, MD, PhD is currently Professor and Director of the Singapore Eye Research Institute, National University of Singapore. He is concurrently Professor at the Center for Eye Research Australia, University of Melbourne. Dr. Wong completed medical school from the National University of Singapore, and ophthalmology residency at the Singapore National Eye Centre. He has medical retinal fellowship training at the University of Sydney and has completed two post-doctoral research fellowships, at the Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital (1997) and at the University of Wisconsin, Madison (2001). He holds a MPH and PhD degrees from the Johns Hopkins University School of Public Health.

Dr. Wong's clinical and research expertise is in the area of retinal vascular diseases, including diabetic and hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration. He has published more than 400 peer-reviewed scientific articles, and presented more than 150 named and invited lectures.

Dr. Wong is on the Editorial Board of the American Journal of Ophthalmology, Investigative Ophthalmology and Visual Sciences, Ophthalmic Epidemiology and Diabetes Care. He has been recognized internationally with numerous awards, including the Sandra Doherty Award from the American Heart Association (2004), the Alcon Research Institute Award, USA (2006), the Novartis Prize in Diabetes (Global, Young Investigator) (2006), the Commonwealth Health Minister's Award for Excellence in Health and Medical Research (2006), the Australian Society of Medical Research AMGEN Medical Research of the Year Award (2007) for "outstanding contribution to translational research" and most recently, the Singapore Translational Researcher Award (STaR) (2008).

Consultant or Advisory Board: Novartis, Pfizer, Allergan
Honoraria: Novartis, Pfizer, Allergan
Research funding/Travel Support: Novartis, Pfizer, Allergan

Sophie J. Bakri, MD is an Associate Professor of Ophthalmology at the Mayo Clinic, Rochester, Minnesota, USA. Her clinical interests are in diseases and surgery of the retina and vitreous, in particular, age-related macular degeneration, diabetic retinopathy, and repair of complex retinal detachments. She undertakes both clinical and translational research in the pathogenesis and treatment of retinal diseases.

Dr Bakri completed a 2 year vitreoretinal surgery fellowship at the Cleveland Clinic Foundation, Cleveland, Ohio, USA. She completed her residency at the Albany Medical College, New York, USA, where she was elected Chief Resident. She graduated from the Queen's Medical Center, University of Nottingham Medical School, England, where she obtained her degree in Medicine and Surgery, and Bachelor of Medical Sciences. Dr Bakri is Board-Certified by the American Board of Ophthalmology.

Dr Bakri has authored over 70 peer-reviewed papers and 13 book chapters on retinal diseases. She is a principal investigator on numerous multicenter clinical trials on novel drugs for retinal disease. Dr Bakri is the Editor-in-Chief of the book "Mayo Clinic on Vision and Eye Health", and on the Editorial Board of the journals Retina, Seminars in Ophthalmology and Clinical and Surgical Ophthalmology. She is a member of the American Society of Retina Specialists, the Macula Society, and has received the Achievement Award from the American Academy of Ophthalmology. Dr Bakri is actively involved in teaching residents and fellows, and is the Director of the Vitreoretinal Surgical Fellowship at Mayo Clinic. She has presented her work and been an invited speaker at national and international meetings on numerous occasions.

Research Support: Genentech, Regeneron
Consultant: Genentech, Allergan

Valérie Biousse, MD is the Cyrus H. Stroner Professor of Ophthalmology, Professor of Ophthalmology and Neurology at the Emory University School of Medicine. She received her medical degree from the University of Paris VI (Pitié-Salpétriere) in Paris, France. She also holds a masters of science from the same university. She trained as an academic neurologist in Paris, where she also completed a stroke fellowship. She came to Emory for a clinical research fellowship in neuro-ophthalmology and subsequently completed an internal medicine internship and an ophthalmology residency at Emory University (Atlanta, GA). Dr. Biousse joined the Department of Neurology in 1998, and the department of Ophthalmology at Emory University in 2002.

The author or coauthor of more than 150 publications and more than 70 teaching articles and book chapters, Dr. Biousse's most notable work is on ocular manifestations of cerebrovascular disease. She is one of the editors for the 6th edition of the major textbook in Neuro-Ophthalmology, the "Walsh & Hoyt Clinical Neuro-Ophthalmology". She is serving on the editorial boards of the American Journal of Ophthalmology, the Journal of Neuro-Ophthalmology, and she is Section Editor for Reviews in Neurological Diseases. She is an active member of the American Academy of Neurology, the American Neurologic Association, the American Heart Association, the American Academy of Ophthalmology, the North American Neuro-Ophthalmology Society, the International Neuro-Ophthalmology Society, the French Society of Neurology, the French Society of Ophthalmology, and the French Society of Stroke.

Research Support: Research to Prevent Blindness, Knight Templar Foundation.

David J. Browning, MD, PhD received his medical degree and doctoral degree in pharmacology from Duke University. He completed a medical internship and ophthalmology residency at Duke University, followed by a combined medical and surgical retina fellowship at the Bascom Palmer Eye Institute. He was a Heed Fellow.

Dr. Browning has been a co-author in 78 journal publications and 5 book chapters, primarily in the field of retinal diseases. He has received the Honor Award from the American Academy of Ophthalmology, been an examiner for the American Board of Ophthalmology, and written questions for the Board's PORT examination. He has a particular interest in clinical trials in retinal diseases and has served in on many committees and contributed patients for all the protocols of the Diabetic Retinopathy Clinical Research Network. He has been active in resident teaching at Carolinas Medical Center and for many years has served in third world ophthalmic mission trips.

Dr. Browning has practiced at Charlotte Eye, Ear, Nose, and Throat Associates in Charlotte, NC for 22 years.

Consultant or Advisory Board: JAEB Center for Health Research.
Equity Owner: Zeiss
Research Support: Genentech, ISIS Pharmaceuticals, Sirion, Novartis, Regeneron, Allergan.

Louis B. Cantor, MDis a Chair and Professor at the Indiana University School of Medicine and Director of the Glaucoma Service. He completed his undergraduate and graduate medical education at Indiana University and was an Ophthalmology Resident at Indiana University, graduating in 1984. In 1985, he completed his glaucoma fellowship at Wills Eye Hospital in Philadelphia under the direction of George L. Spaeth, MD. Dr. Cantor served as the Ophthalmology Residency Program Director at the Indiana University School of Medicine from 1996 to 2006, is presently Chair of the Ophthalmology Residency Review Committee and Chair of the Council of Review Committee chairs of the ACGME, and is Secretary for Ophthalmic Knowledge for the AAO.. Dr. Cantor is an attending physician at several Indianapolis area hospitals, including Clarian Health Systems, Indiana University and Riley Hospitals, Wishard Memorial Hospital, and the Roudebush Veterans Administration Hospital. Dr. Cantor is a member and past President of the Indiana Academy of Ophthalmology, a past President of the Spaeth Glaucoma Fellow Society, past President of the Indianapolis Ophthalmological Society, past Treasurer of the American Glaucoma Society, current Chairman of the Medical Advisory Board for Prevent Blindness Indiana, and President of the Glaucoma Research and Education Foundation, Inc.

Dr. Cantor serves on the Editorial Review Board for the American Journal of Ophthalmology and has been an invited reviewer for Ophthalmology, American Journal of Ophthalmology, Archives of Ophthalmology, Clinical Therapeutics, Glaucoma, and other medical journals.

Dr. Cantor is a frequent invited lecturer and is the recipient of multiple grants and has published over 100 abstracts and 80 peer reviewed publications.

Consultant or Advisory Board : Allergan, AMO, Glaukos, QLT
Honoraria: AMO, iScience, Heidelberg
Research Support: Allergan, Alcon, Pfizer, Glaukos

James Chodosh, MD, MPH is a Lecturer in Ophthalmology at the Massachusetts Eye and Ear Infirmary – Harvard Medical School. Dr. Chodosh received his medical degree from Baylor College of Medicine in Houston, Texas, completed residency training in Ophthalmology at Baylor, clinical fellowship training in Corneal and External Diseases and Surgery at the Bascom Palmer Eye Institute in Miami, and a postdoctoral research fellowship in Virology & Molecular Biology and Infectious Diseases at St. Jude Children's Research Hospital in Memphis. Dr. Chodosh served on the faculty of the University of Tennessee College of Medicine from 1993 to 1995, and at the Dean McGee Eye Institute - University of Oklahoma College of Medicine from 1995 to 2008, where he rose to Professor of Ophthalmology and held the M.G. McCool Chair in Ophthalmology.

Dr. Chodosh was elected to the Alpha Omega Alpha Honor Medical Society, and later received the prestigious Heed Fellowship. He has received three merit awards from Research to Prevent Blindness, including a Career Development Award, the Lew R. Wasserman Award, and most recently the Physician Scientist Award. He has been chosen on numerous occasions as a Best Doctor in America.

Dr. Chodosh has published over 100 articles, book chapters, and abstracts, has given over 130 talks and invited lectures, and has been funded for 15 years by the National Eye Institute for his research on ocular adenovirus infections. He was a founding member of the Molecular Pathogenesis of Eye Infection Research Center, and organizer of the Public Health Working Group in Ophthalmology. Dr. Chodosh was Chair of the Anterior Eye Disease Study Section for the National Institutes of Health, President of the Ocular Microbiology & Immunology Group, Co-Editor of Duane's Foundations of Clinical Ophthalmology - Ocular Microbiology Section, Councilor to the American Academy of Ophthalmology, and an Associate Examiner for the American Board of Ophthalmology. He is an Executive Editor for Cornea and External Diseases for the American Journal of Ophthalmology, and performs peer review on a regular basis for 19 additional journals. He served on the American Academy of Ophthalmology Basic and Clinical Science Course Cornea/External Disease Subcommittee, and is currently on the Knowledge Base-Cornea/External Disease-Panel Subcommittee, and the Research and Regulatory Affairs Committee. He is a member of the American Association of Immunologists, American Society for Virology, the Association for Research in Vision & Ophthalmology, and the American Ophthalmological Society. He is also now a member of the National Advisory Eye Council for the National Eye Institute.

Research Support: National Eye Institute.

Dr. Joseph Caprioli, MD is a David May II Professor of Ophthalmology at the UCLA, Department of Ophthalmology, David Geffen School of Medicine, and Chief of the Glaucoma Division at the Jules Stein Eye Institute.

Dr. Caprioli received both his Bachelor of Science and medical degree from the State University of New York. He completed his surgical internship and ophthalmology residency at the Yale University School of Medicine, followed by fellowship training with Dr. George Spaeth in glaucoma at the Wills Eye Hospital. Dr. Caprioli was appointed to the full time faculty at Yale in 1984, and served as Director of the Glaucoma Section until 1997, having achieved the rank of tenured Professor in 1993. In 1997, he was named the Frances and Ray Stark Professor of Ophthalmology and Chief of Glaucoma at UCLA.

Dr. Caprioli's clinical research involves the functional and structural assessment of the optic nerve for the early and serial detection of glaucomatous damage. He was the recipient of the Alcon Research Institute Award for this and related research. Dr. Caprioli's basic research includes the study of the mechanisms of damage to the retinal ganglion cell in glaucoma. Dr. Caprioli's research group has demonstrated that certain endogenous stress proteins protect cells against diverse forms of damage to retinal ganglion cells, for which he was awarded the Lewis Rudin Glaucoma Prize in 1998. He is also the recipient of the Jules Francois Prize of the Belgian Ophthalmological Society for research in optic nerve damage in glaucoma; the Honor Award, Senior Achievement Award, and Secretariat Awards of the American Academy of Ophthalmology; the Wasserman Merit Award and the Physician Scientist Award from Research to Prevent Blindness; and the Physician-Scientist Award of the American Glaucoma Society.

Dr. Caprioli has taught and published extensively in all aspects of glaucoma diagnosis and treatment, anterior segment surgery, and laser techniques, with over 300 scientific publications. In addition to serving on the Editorial Board of the American Journal of Ophthalmology, he also serves on the Editorial Board of Investigative Ophthalmology and Visual Science. He is the Glaucoma Section Editor for Duane's Ophthalmology.

Dr. Caprioli has presented numerous guest lectures and named lectures internationally. He has trained numerous clinical and research fellows, many of whom now hold full-time faculty positions in academic centers worldwide.

Alcon: consultant, grant support, lecture fees
Allergan: consultant, grant support, lecture fees
Pfizer: consultant, grant support

David K. Coats, MD is Chief of Ophthalmology at Texas Children's Hospital and Professor of Ophthalmology at Baylor College of Medicine in Houston, Texas. He received his medical degree from Texas Tech University School of Medicine in 1987, followed by internship in South Carolina, and residency at the Storm Eye Institute at the Medical University of South Carolina. He completed a fellowship in Pediatric Ophthalmology and Adult Strabismus at Indiana University in Indianapolis, Indiana in 1994.

Dr. Coats has published more than 90 peer-reviewed articles and is co-author of the textbook Strabismus Surgery and its Complications. Dr. Coats is Chair of the Ophthalmic Knowledge and Assessment Program (OKAP) and Pediatric Subspeciality Information Team, both committees of the American Academy of Ophthalmology. Dr. Coats is on the Board of Directors of the Pan American Association of Ophthalmologists and is a Councilor for the Texas Ophthalmologic Association.

Dr. Coats joined the faculty of the Cullen Eye Institute at Baylor College of Medicine in 1996.

Dr. Nathan Congdon, MD, MPH is a Professor of Ophthalmology and Public Health at the Chinese University of Hong Kong, and is also affiliated with the Joint Shantou International Eye Center in the PRC and with Helen Keller International, one of the largest blindness prevention organizations in the US. Dr. Congdon's research focuses on improving the quality of service delivery for cataract, refractive error and glaucoma programs in Asia. He has over 80 peer-reviewed publications, and has received awards and funding support from the Heed Foundation, the NIH, USAID, APAO, Oxford University and the World Bank. Dr Congdon received his AB degree from Princeton University and MPhil from Cambridge University, both in Chinese literature, and speaks and writes Chinese fluently. His medical and public health degrees and residency and chief residency training in ophthalmology were obtained from the Johns Hopkins University School of Medicine, and he completed a fellowship in glaucoma with George Spaeth at Wills.

Honoraria: Reichert Instruments, Pfizer
Travel expenses: Reichert Instruments, Pfizer
Research Support: Reichert Instruments

Michel E. Farah, MD is Professor of Ophthalmology and Head of Retina Vitreous Department of the Federal University of São Paulo in São Paulo, Brazil. He also serves as Post-Graduation Advisor and Director of the Ophthalmic Technology Course. He did his residence at Hospital dos Servidores do Estado Rio de Janeiro and his fellowship in retina-vitreous disease at Federal University of São Paulo. Dr. Farah also received a research fellowship from the Bascom Palmer Eye Institute of the University of Miami School of Medicine. Dr. Farah is a member of the Club Jules Gonin, Macula Society, Retina Society and American Society of Retina Specialists, and has received numerous awards. He has been past President of the Brazilian Retina Vitreous Society and is a Delegate of the Pan American Association of Ophthalmology. He is Involved in prevention of blindness programs, teaching, and the Scientific and Fund Raiser Boards within the Brazilian Council of Ophthalmology. He also created the Diabetic Eye Continuous Campaign. Dr. Farah served as President of the Brazilian Congress of Ophthalmology in 2001 and Treasurer of the World Congress of Ophthalmology in 2006, and has been invited to present the PAAO American Journal of Ophthalmology Lecture at the American Academy of Ophthalmology in San Francisco, CA in 2009.

Dr. Farah has been very active in eye research and development. He was the Principal Investigator for over 20 multicenter trials evaluating new drugs, devices, surgical innovations, and drug delivery for diabetic retinopathy, macular degeneration and edema. He is a peer reviewer for several journals and the current Associate Editor of the American Journal of Ophthalmology and Brazilian Archives of Ophthalmology. With regard to his publications, he is the author of four books and 101 chapters in several books and has a total of 164 peer-reviewed articles (90 in Brazilian and 74 in international journals).

Sharon Fekrat, MD, FACS is an Associate Professor of Ophthalmology and maintains a busy vitreoretinal surgical practice at the Duke University Eye Center's Albert Eye Research Institute. She is the Chief of Ophthalmology at the Durham Veterans' Affairs Medical Center.

Dr. Fekrat completed her residency training at The Wilmer Ophthalmological Institute of Johns Hopkins Medical Institutions. At Wilmer, she then completed two years of fellowship training in diseases and surgery of the retina and vitreous, after which she served one year as the Assistant Chief of Service and Director of Ocular Trauma at Hopkins. Her professional activities have focused on that subspecialty, with a particular interest in novel treatment options for retinal venous occlusive disease. She is the site Principal Investigator at Duke for multiple multicenter clinical trials in retinal venous occlusive disease and age-related macular degeneration.

Dr. Fekrat is a fellow of the American Academy of Ophthalmology and has served the AAO on many committees as both a Chair and member. She has received the AAO Secretariat Award several times. She has served as the Secretary/Treasurer, Vice President, President Elect, President, and Past President of the North Carolina Society of Eye Physicians and Surgeons. She received the AAO's State Affairs Star Award for organizing the regional ophthalmology resident and fellows Meeting of the Minds. She received the 2009 Honor Award from the American Society of Retina Specialists.

Dr. Fekrat serves on the Editorial Board of the American Journal of Ophthalmology, Retinal Physician, as well as the American Academy of Ophthalmology's Eyenet. She served as an Associate Examiner for the American Board of Ophthalmology. Dr. Fekrat is extensively published. She is co-author of the book Ophthalmic Ultrasound, is editor of Curbside Consultation in Retina: 49 Clinical Questions, and is co-editor of the book for patients, All About Your Eyes. She is recognized by her peers as a top ophthalmologist in Business North Carolina.

Consultant or Advisory Board: Allergan, Genentech
Patent Royalty: Alcon

Harry W. Flynn, Jr., MD is the J. Donald M. Gass, MD Distinguished Chair in Ophthalmology at the University of Miami School of Medicine. He is Professor of Ophthalmology at the Bascom Palmer Eye Institute and specializes in medical and surgical treatment of diseases of the retina and vitreous. He received a Bachelor of Science Degree at Wake Forest University in 1967 and his Doctor of Medicine Degree at the University of Virginia, School of Medicine in 1971. After an internship at the Pacific Medical Center in San Francisco, Dr. Flynn had two years of active duty in the United States Army at the Brook Army Medical Center in San Antonio (1976-1978).

Dr. Flynn has been author or co-author of more than 300 publications as well as 53 book chapters. He has edited or co-edited four books including Diabetes and Ocular Diseases: Past, Current, and Future Therapies and Vitreoretinal Disease: The Essentials. Dr. Flynn had held numerous administrative positions including President: The Vitreous Society (1992-1993), President: The Miami Ophthalmological Society (1999) and President: The Retina Society (2002-2003). Dr. Flynn has served as Senior Editor for Section 12 (Retina) of the Basic and Clinical Science Course for the American Academy of Ophthalmology. He has also served as Co-Director of the Retina Subspecialty Day for the American Academy of Ophthalmology. He serves on the Editorial Board of numerous journals including the American Journal of Ophthalmology, RETINA, Ophthalmic Surgery and Lasers, and Evidence Based Ophthalmology. He currently serves on the Data and Safety Monitoring Committees for DRCR Network and SCORE Studies. He received the AAO Life Achievement Honor Award in 2008.

Consultant or Advisory Board: Alcon, Allergan, Carl Zeiss Meditec, Genentech, Pfizer
Honoraria: Optimedica

Alain Gaudric, MD is Professor and Chairman of the Department of Ophthalmology, at the Lariboisière Hospital, University of Paris 7 Denis Diderot, since 1993. He completed his fellowship at the Department of Ophthalmology of Creteil, University of Paris 12.

He is a member of, the Club Jules Gonin of which he has been a member of the Committee, the Macula Society, the American Academy of Ophthalmology, the French Ophthalmological Society and he is a member of the Board of the European Society of Retina Specialists (EURETINA). Dr Gaudric has received the Prize of the Retinal Research Foundation 2006 for his Jules Gonin lecture.

He served in the Ophthalmology section of the French National Council of Universities, and is involved in the teaching program for the residents in Ophthalmology. Dr. Gaudric's clinical and research interests focus on retinal diseases, with a particular emphasis on macular surgery, retinal vascular diseases and retinal imaging. He published about 200 articles in peer reviewed journals as well as book chapters and edited 2 books. He serves as a member of the Editorial Board of the American Journal of Ophthalmology and of the Journal Français d'Ophtalmologie.

Dr Gaudric has a particular interest in clinical trials and serves as principal investigator for many multicenter clinical trials in retinal vascular disease, age-related macular degeneration and macular surgery.

Dr Gaudric has been an invited speaker at numerous national and international conferences on a wide range of medical and surgical topics.

Consultant or Advisory Board: Allergan, Novartis, Thrombogenics
Travel support: Novartis, Allergan
Research Support (department): Novartis, Allergan, Alcon

David S. Greenfield, MD is Professor of Ophthalmology and Director of the Glaucoma Fellowship Program at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL. He earned his medical degree from the New York University School of Medicine in 1990 and completed his residency at the New England Eye Center, Tufts University School of Medicine, Boston, in 1994. Dr. Greenfield completed a 1994-5 Heed Fellowship in Glaucoma and a 1995 Heed-Knapp Fellowship in Neuro-Ophthalmology at the Bascom Palmer Eye Institute, University of Miami School of Medicine. He previously joined The New York Eye & Ear Infirmary in 1996 as Clinical Assistant Professor of Ophthalmology and Neurology.

Dr. Greenfield is a member of the editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, Ophthalmic Surgery Lasers and Imaging, and International Glaucoma Review. He currently serves as chair of the American Glaucoma Society Bylaws and Strategic Planning Committee, chair of the World Glaucoma Association Bylaws Committee, is Vice-Chair of the AGS Scientific Program Committee, and is a member of the AAO Glaucoma Subspecialty Day Committee and Technology Assessment Committee. Dr. Greenfield has served as Co-Chairman of the Glaucoma Subspecialty Day of the American Academy of Ophthalmology (2003-4), and was awarded the 2003 American Academy of Ophthalmology Achievement Award.

Dr. Greenfield has taught and published extensively in all aspects of glaucoma diagnosis, monitoring, and therapy. His research interests include optic disc and retinal nerve fiber imaging, reflectance properties of the retinal nerve fiber layer, normal-tension glaucoma, bleb-related ocular infection, and complex glaucoma filtration surgery. He is the recipient of a National Eye Institute consortium grant studying advanced imaging technology in glaucoma, and has received funding from the NIH since 1999. He has delivered numerous guest lectures and named lectures nationally and internationally, and has published over 210 original scientific papers, abstracts and book chapters. He has trained numerous clinical and research Fellows, many of whom hold distinguished academic positions worldwide.

Consultant or Advisory Board: Pfizer, Allergan, Alcon, Topcon, Optovue
Speaker's Bureau: Pfizer, Allergan, Alcon
Lectures: Pfizer, Allergan, Alcon, Optovue
Research Support: National Eye Institute, Pfizer, Allergan, Carl Zeiss Meditec, Heidelberg Enginering

Seenu M. Hariprasad, MD is an Associate Professor of Ophthalmology at the University of Chicago, Department of Surgery, Pritzker School of Medicine, where he serves as Chief of the Vitreoretinal Service.

After receiving his Bachelor of Arts degree from Cornell University and graduating with Distinction in Neuroscience, Dr. Hariprasad went on to receive his Medical Degree from the University of Pennsylvania where he was elected into AOA. He completed both his transitional internship and ophthalmology residency at Baylor College of Medicine's Cullen Eye Institute where he received numerous research awards. Dr. Hariprasad then spent 2 years at Washington University's Barnes Retina Institute where he completed a Fellowship in the Diseases and Surgery of the Retina, Macula, and Vitreous.

Dr. Hariprasad is actively involved in clinical research, having been principal investigator or sub-investigator in more than 30 national clinical trials evaluating new drugs, devices, surgical innovations, and drug delivery for age- related macular degeneration, retinal vascular occlusion, endophthalmitis and diabetic retinopathy. His efforts in research have resulted in more than 80 peer-reviewed publications, meeting abstracts and textbook chapters. He currently holds the position of Director of Ophthalmic Clinical Research at the University of Chicago.

In addition to serving on the Editorial Board for the American Journal of Ophthalmology, Dr. Hariprasad is also a Scientific Referee for 6 major ophthalmology journals. Additionally, he serves on the Editorial Board for Retinal Physician and EyeTube.net, an ophthalmic surgical video website. He is also co-founder of the CONNECT Network, a collaborative association of academic vitreoretinal specialists devoted to furthering the vitreoretinal subspecialty through various research endeavors.

Dr. Hariprasad has presented a vast number of lectures at scientific meetings, as well as guest lectureships both nationally and internationally. He has trained numerous residents and currently is Director of the Surgical Retina Fellowship Program at the University of Chicago.

Dr. Hariprasad is Board certified by the American Board of Ophthalmology and is a member of the American Medical Association, American Academy of Ophthalmology, American Society of Retinal Specialists, Association for Research in Vision and Ophthalmology, and The Chicago Ophthalmological Society. In 2007 and 2009,, the Consumer Research Council of America selected him as one of "America's Top Ophthalmologists."

Consultant or Advisory Board: Genentech, Alcon, Pfizer, OD-OS, and Ocular Therapeutix
Speaker Bureau: Genentech, Alcon, Allergan

Nancy M. Holekamp, MD is an Associate Professor of Clinical Ophthalmology and Visual Sciences at the Washington University School of Medicine in St. Louis, Missouri. She is also a partner in the Barnes Retina Institute. Dr. Holekamp received her undergraduate Bachelor of Arts degree from Wellesley College Summa cum Laude. She received her Medical Degree from the Johns Hopkins School of Medicine. Dr. Holekamp completed an internship in internal medicine and a residency in ophthalmology at the Washington University School of Medicine. Her fellowship training in vitreoretinal surgery was with the Retina Consultants (now the Barnes Retina Institute) in St. Louis.

Dr. Holekamp is actively involved in clinical research, having been principal investigator or sub-investigator in more than 15 national clinical trials dealing with age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy. Her efforts in research have resulted in more than 50 peer-reviewed publications, more than 15 book chapters, and numerous speaking invitations both nationally and internationally. She is a member of the major subspecialty societies, including membership on the Executive Committee of the Macula Society. She acts as a reviewer for four major ophthalmology journals and as a consultant to two ophthalmic pharmaceutical companies. After 6 years on the American Academy of Ophthalmology Ethics Committee, she has developed an interested in medical ethics.

Consultant or Advisory Board: Genentech, Alcon
Speaker Bureau: Genentech
Lecture Fees: Stratamed Corporation
Research Support: Genentech, Allergan, Alcon

Douglas A. Jabs, MD, MBA is Professor and Chairman of the Department of Ophthalmology at the Mount Sinai School of Medicine in New York. Prior to that he was The Alan C. Woods Professor of Ophthalmology and Professor of Medicine at The Johns Hopkins University School of Medicine and is Professor of Epidemiology at The Johns Hopkins University Bloomberg School of Public Health, and the Director of the Division of Ocular Immunology at The Wilmer Eye Institute. He received his undergraduate degree from Dartmouth College and his MD from The Johns Hopkins University School of Medicine. He completed an internship in internal medicine at the Cornell Medical Center/New York Hospital, a residency in internal medicine at The Johns Hopkins Hospital, a residency in ophthalmology at The Wilmer Eye Institute, and a fellowship in rheumatology at The Johns Hopkins Medical Institutions. In 1984, he joined the faculty at The Johns Hopkins University School of Medicine and was promoted to Professor in both Ophthalmology and Medicine in 1993. He received a Masters of Science in Business from Johns Hopkins University in 1998, and in 2000, received a Masters in Business Administration from Johns Hopkins University. In 2007, he became Chairman of the Department of Ophthalmology at the Mount Sinai School of Medicine in New York.

Dr. Jabs has been the recipient of such honors and awards as the Research to Prevent Blindness Olga Keith Wiess Scholar Award, the Research to Prevent Blindness Lew R. Wasserman Merit Award, the Research to Prevent Blindness Senior Scientific Investigator, the American Academy of Ophthalmology Achievement Award and Senior Achievement Award, and the Ethel Baxter Award for Excellence in Research from the Sjögren's Syndrome Foundation. He was President of the American Uveitis Society from 2000-2002. He was a member of the Council of the American Academy of Ophthalmology, where he represents the American Uveitis Society. He served on the National Eye Institute's Visual Sciences A Study Section from 1994 to 1998, the Association for Research in Vision and Ophthalmology's (ARVO) planning committee for the Immunology and Microbiology Section from 2000-2003, and served on the National Eye Institute Intramural Program's Data and Safety Monitoring Committee from 2001 to 2009.

Dr. Jabs has held funding from the National Eye Institute since 1986. He is the chairman of the Studies of Ocular Complications of AIDS (SOCA) Research Group, a clinical trials program which has been in existence since 1988, has conducted five randomized, multicenter, controlled, clinical trials on the treatment of cytomegalovirus retinitis, and now conducts an ongoing multicenter, prospective, cohort study of patients with AIDS for ocular complications and visual outcomes. He is chairman of the Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, which is conducting randomized, controlled, clinical trials of treatments for severe uveitis. His other research interests include the immunopathogenesis of autoimmune ocular disease, the epidemiology, molecular biology and clinical consequences of resistant cytomegalovirus among patients being treated for cytomegalovirus retinitis, the treatment of uveitis, and the immunopathogenesis of autoimmune ocular and lacrimal gland inflammation. He has authored or coauthored over 214 publications and 44 book chapters. His areas of expertise include the treatment of uveitis and other ophthalmic inflammatory disorders, the ocular complications of autoimmune disease, of immune deficiency and of immune suppression, cytomegalovirus retinitis, and the immunology of autoimmunity.

Consultant or Advisory Board: Roche Pharmaceuticals, Ciba Vision, Bayer Corporation, Novartis, Centocor, SmithKline Beecham, Genzyme, EMMES Corporation, Allergan.
Equity Owner: Amgen, Johnson & Johnson, and Merck
Research Support: Bausch & Lomb, Roche.

Mark W. Johnson, MD is Professor of Ophthalmology and Visual Sciences and Director of the Retina Service at the University of Michigan in Ann Arbor. An honors graduate of the University of Utah School of Medicine, Dr. Johnson completed residency training at the University of Michigan Kellogg Eye Center where he served as Chief Resident. He completed a year of medical retina fellowship with Dr. Donald Gass at the Bascom Palmer Eye Institute, followed by a year of fellowship training in vitreoretinal surgery at the same institution.

Dr. Johnson is a fellow of the American Academy of Ophthalmology and received its Honor Award in 1997 and its Senior Achievement Award in 2005. He was elected to active membership in the American Ophthalmological Society in 2005, and is recognized in Best Doctors in America and Guide to America's Top Physicians. He has served as Associate Examiner for the American Board of Ophthalmology since 1995. He serves on the editorial boards of the American Journal of Ophthalmology, Retina, and Retinal Physician.

Dr. Johnson has served on the Board of Directors of the American Society of Retina Specialists and as chairperson for committees of the Macula and Retina Societies. He currently serves as Secretary of the Retina Society. He has served as a member of the Update/Special Focus Course Committee and the Basic and Clinical Science Course Committee of the American Academy of Ophthalmology, the Committee on programs of the American Ophthalmological Society, and the Periodic Ophthalmic Review Tests (PORT) Panel of the American Board of Ophthalmology.

Dr. Johnson's chief clinical research interests include pharmacotherapies for macular diseases and pathogenesis and treatment of vitreomacular interface disorders. He has served as principal investigator and Data and Safety Monitoring Committee member for numerous national multicenter clinical trials in age-related macular degeneration, retinal vascular disease, and vitreoretinal disorders. He lectures widely on topics in macular and vitreoretinal disease and has published over 125 articles and book chapters.

Consultant: Oraya Therapeutics
Research Support: Regeneron, Thrombogenics, GlaxoSmithKline

Malik Kahook, MD is an Associate Professor and Director of the Glaucoma Service in the Department of Ophthalmology at the University of Colorado. He is also a faculty member in the Department of Bioengineering at the University of Colorado. He specializes in the medical and surgical care of glaucoma and cataracts. He is active within the ophthalmology community including memberships in AAO, AGS, ASCRS, and ARVO. He is involved in research funded by industry and foundations. Research interests include novel surgeries to treat glaucoma, imaging of the eye and both clinical and basic science pharmacology studies. He has authored more than 120 peer reviewed manuscripts, abstracts and book chapters. Doctor Kahook was awarded an AGS Clinician-Scientist Fellowship Award for 2007 as well as the AGS Compliance Grant for 2006 and was named New Inventor of the Year for the University of Colorado in 2009. He is regularly invited to lecture on topics involving glaucoma and cataract surgery across the country and around the world.

Dr. Kahook completed his residency training at the University of Colorado, Rocky Mountain Lions Eye Institute in Denver, CO, where he was named Chief Resident. He then went on to complete his fellowship in glaucoma at the University of Pittsburgh Medical Center in Pittsburgh, PA.

Research and Consulting Disclosures: Alcon, Allergan, Pfizer, Merck, Genentech, Actelion, the State of Colorado & the United States Food and Drug Administration.

Peter K. Kaiser, MD graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute at the Cleveland Clinic Foundation, Cleveland, Ohio.

As a National Institute of Health funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in age-related macular degeneration and diabetic retinopathy. In addition, Dr Kaiser is actively involved in clinical research as Study Chairman of 5 major, multi-center, international clinical trials, and principal investigator in over 30 trials evaluating new treatments for AMD, DR, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR), which is the OCT coordinating center for over 25 multi-center, clinical trials. Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored four textbooks, and more than 150 peer-reviewed papers. He is Editor-in-Chief of Current Concepts in Retina, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today, Retinal Physician, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Achievement and Senior Achievement Awards, and is listed as one of the "Best Doctors in America." He is the team ophthalmologist for the Cleveland Browns (National Football League), Cleveland Cavaliers (National Basketball Association), and the Cleveland Indians (Major League Baseball).

Consultant or Advisory Board: ArcticDx, Alcon, Allergan, Genentech, Occulogix, Ophthotech, Oraya, Novartis, Regeneron, QLT
Research Support: National Eye Institute, Alcon, Allergan, Genentech, Merck, Novartis, Pfizer, Regeneron, SIRNA, TargeGen, Quark, QLT, OSI-Eyetech, Genaera, Acuity, GlaxoSmithKline, MacuSight, Novagali, Occulogix, Opko, Potentia, Therasight

Andrew G. Lee, MD is a graduate of the University of Virginia School of Medicine in 1989. He completed his ophthalmology residency and was the chief resident at Baylor College of Medicine in Houston, Texas from 1990-1993. Following residency, Dr. Lee completed a fellowship in neuro-ophthalmology at the Wilmer Eye Institute and was a post-doctoral Fight for Sight fellow at the Johns Hopkins Hospital in Baltimore, Maryland from 1993-1994. He was formerly an Associate Professor at Baylor College of Medicine and Adjunct Associate Professor at the MD Anderson Cancer Center in Houston from 1994-2000. Dr. Lee was an Associate and then Full Professor of Ophthalmology, Neurology, and Neurosurgery at the University of Iowa Hospitals and Clinics and on April 1, 2009 will assume the chair of ophthalmology at The Methodist Hospital in Houston, Texas. He will be a Professor of Ophthalmology at Weill Cornell Medical College. He has published over 260 peer reviewed articles and 50 book chapters and has authored three full textbooks in ophthalmology. He is listed in Best Doctors in America, received the Achievement Award and the Secretariat Award from the American Academy of Ophthalmology, and was the 2001 recipient of the Charles Phelps Memorial Award for Research and Education. In addition to the AJO, Dr. Lee serves on the editorial board of 12 other journals and is Editor in Chief of the Journal of Academic Ophthalmology.

Steven L. Mansberger, MD, MPH is an Associate Scientist and Director of Ophthalmic Clinical Trials for the Devers Eye Institute in Portland, Oregon. He is also the Director of Glaucoma Services at the Veterans Hospital, and holds appointments at Oregon Health Science University (OHSU) as Adjunct Assistant Professor of Ophthalmology and Clinical Assistant Professor of Public Health and Preventive Medicine.

Dr. Mansberger completed his medical degree from Indiana University School of Medicine, an ophthalmology residency at Shiley Eye Center at the University of California, San Diego, and a glaucoma fellowship at Devers Eye Institute. He also earned a Masters in Public Health degree (MPH-Biostatistics/Epidemiology) from OHSU.

Dr. Mansberger has research grant support as principal investigator from the National Eye Institute, Center for Disease Control and Prevention, and the American Glaucoma Society. He has won numerous awards including "Best Doctors in America", Heed Fellowship, The Robert Watske Ophthalmology Instructor of the Year, American Glaucoma Society Clinician-Scientist award, among others. He is on the Editorial Board for Journal of Glaucoma and American Journal of Ophthalmology. He is an invited reviewer for Archives of Ophthalmology, British Journal of Ophthalmology, Ophthalmology, Investigative Ophthalmology and Visual Science, Survey of Ophthalmology, as well as 4 other journals. He has authored over 100 journal articles, book chapters, and abstracts.

Consultant or Advisory Board: Allergan, Pfizer, Santen
Lectures: Allergan, Pfizer, Heidelberg
Research Support: National Eye Institute, Centers for Disease Control, Alcon

Rupert M. Menapace, MD graduated in medicine "summa cum laude" in 1980 at the University of Vienna Medical School and obtained full professorship there in 1995. He is the founder and director of the Intraocular Lens Service at the Vienna Medical University. Apart from cataract and intraocular lens implant surgery he has gained wide experience with trauma and reconstructive anterior segment surgery. He has also worked in the field of surgical glaucoma, as well as irradiation and surgical treatment of intraocular melanoma on which he wrote his professorial dissertation.

As by 2007, he published over 180 papers in peer-reviewed journals, and numerous other papers and reviews for national and foreign journals, as well as several book chapters. He was vice president of the "German-speaking Society of Intraocular Lens Implantation and Refractive Surgery" and has been a faculty member of numerous other national and international professional organisations. He has regularly lectured at the annual "Congress of German Ophthalmic Surgeons"(DOC). He held a DOC "Ridley Lecture" and was awarded for the "Best German Ophthalmologic Publication". He is listed in best-in-their-field list of leading researchers of the German-speaking medicine (GaM) by the Society of Applied Meta-Research in Erlangen, Germany. He is an Editorial Board Member of the Journal of Cataract and Refractive Surgery since 1998 and Section Co-Editor since 2007, and a regular reviewer for many other peer-reviewed journals.

His research has been focusing on the reduction of after-cataract by improvements in intraocular lens the design and material, capsular implants, and capsular surgery. Evaluation of current accommodative intraocular lenses and the search for alternative concepts has been another field of interest. His current research is concentrating on optimizing instrumentation, implants, and fluidics in conjunction with micro-incision cataract surgery.

Travis A. Meredith, MD, is professor and chairman of the Department of Ohthalmology at the University of North Carolina, Chapel Hill. Dr. Meredith attended Yale University as a National Merit Scholar and graduated from Johns Hopkins University School of Medicine. After internship at Columbia-Presbyterian Hospital, he returned to the Johns Hopkins Wilmer Eye Institute for residency. Dr. Meredith completed a fellowship in retinal disease at the Medical College of Wisconsin where he subsequently served as an assistant and associate professor.

Dr. Meredith has been Professor of Ophthalmology at Emory University and at the Wilmer Institute of the Johns Hopkins University School of Medicine, and a clinical professor of Ophthalmology at St. Louis University and Washington University.

Dr. Meredith has authored over 150 scientific publications, 30 book chapters, and 2 textbooks. He has served as president of the Macula Society, president-elect of the Georgia Society of Ophthalmology, chair of the Council of the AOS and is currently President of the AUPO.. As an active member of the American Academy of Ophthalmology, he has received the Honor Award, Senior Honor Award, Secretariat Award, and Life Achievement Awqard.

Dr. Meredith has a particular interest in clinical trials and serves principal investigator for multiple studies dealing with retinal disease therapies. He was continually funded by the National Eye Institute over an eleven year period for laboratory studies of models of endophthalmitis.

Consultant or Advisory Board: GlaxoSmithKline, Data Monitoring Committee for Pfizer
Research Support: National Eye Institute.

Kohji Nishida, MD, PhD is Professor and Chairman of the Department of Ophthalmology, Osaka University Medical School, Japan.

Kohji Nishida, MD, PhD, received his MD from Osaka University Medical School in 1988, where he also completed his residency in Department of Ophthalmology with subsequent sub-speciality training on the cornea and external diseases. In 1992, he joined the faculty at Kyoto Prefectural University of Medicine, while also continuing his activity in corneal research at Osaka University Medical School. He received his PhD in 1997 from Osaka University Medical School and then undertook research training as a research associate at the Salk Institute (San Diego, CA), where he studied stem cell biology from 1998-2000. In 2000, he then returned to Department of Ophthalmology, Osaka University Medical School as an Assistant Professor where he was promoted to the position of Associate Professor in 2004. During this time Dr. Nishida performed clinical duties and teaching, as well as both clinical and basic research regarding the cornea and external diseases. In 2005, he moved to his current position of Professor and Chairman of the Department of Ophthalmology at Tohoku Graduate University of Medicine.

Dr. Nishida's clinical expertise is in the diagnosis and management of corneal and external diseases, as well as refractive surgery. In particular he has a great interest in the surgical management of ocular surface diseases. His current research interests include the pathogenesis of corneal diseases, the genetics of corneal dystrophy, as well as stem cell biology and tissue engineering of the cornea. His longstanding interests in the treatment of ocular surface diseases via reconstructive surgeries, has recently succeeded in the clinical application of a novel corneal bioengineering technology developed by he and his colleagues. He received the Rhoto Award in 1997, Japanese Ophthalmology Society Award in 1998, ALCON Award in 2004, Pfizer Ophthalmic Award Japan in 2005. Dr. Nishida also serves on the organizing committee for a wide range of academic organizations including the Japanese Ophthalmological Society, the Japan Cornea Society, the Japanese Society for Regenerative Medicine, and the Japanese Society for Biomaterials. He is a frequent guest speaker at national and international meetings and has published over100 peer-reviewed articles and over 50 book chapters in the areas of corneal diseases and surgery, as well as corneal tissue engineering.

Robert B. Nussenblatt, MD

In Brief:
• Attending City College of New York, SUNY Downstate (MD)
• Training in both Internal Medicine and Ophthalmology
• Attended the Advanced Management Program of the Harvard Business School
• Married to Rosine Rossignelly Nusenblatt. 3 children-Veronique, Valerie, and Eric

Area of interest:
• Ocular Immunology with an emphasis on clinical immunology and translational research.
• Medical Ethics and Clinical Trials.
• Has written a large number of protocols. Have interacted with the FDA with two studies as PI used for NDAs.

Established the Laboratory of Immunology, NEI, NIH.
• Fellowship program in immunology. Clinical Fellowship program in Ocular Immunology.

As Scientific Director (1992-2001)
• in Charge of 40 million dollar budget. Full authority for scientific, budgetary, space and personnel matters.
• The spokesperson for the NEI for all intramural matters. Almost daily interaction with the Deputy Director of Intramural Research, Dr. Gottesman. Constant interaction with other Scientific Directors.
• Had been Clinical Director before becoming Scientific Director, thus covering the two major administrative positions for the intramural program at the same time.
• In charge of 37,000 sq ft of program space for laboratory space. 12,000 sq ft for clinical work.
• Overall responsibility for many areas of science: genetics, Immunology including AIDS, Neuroscience, retinal biochemistry and molecular biology, cataract research, diabetes and retinal vascular disorders, cornea and ocular embryology and development, glaucoma.
• At any one time some 300 individuals in the intramural program. About 160 are full time employees for science effort.
• Some 18 full time physicians see patients. Patients are seen under protocol in various clinical areas: dry eye, allergy, uveitis, AIDS, retinal vascular disease, genetics, glaucoma, neuroophthalmology, ocular oncology and strabismus.
• 12,000 outpatient visits per year.
• The Scientific Director is responsible for the mentoring program and assuring a positive scientific experience for young investigators.
• Established core facilities for: gene therapy, confocal microscopy and in situ hybridization, and microarray techniques. Groups emphasizing mass spectroscopy and proteinomics.

Adminstratively:
• Served on large number of committees intramurally: search committees for clinical directors, scientific directors; served as the sole scientist on the New Business System steering committee, and chairing committee for the new CRIS committee-computer for hospital and clinical research.
• Chairing intramural committee for the implementation plan for Clinical research conduct and patient safety. To be harmonized with recommendations for the outside committee.
• As ARVO president, organized that group's first retreat and strategic plan which is now being implemented. One of the goals of the strategic plan was to protect the present system of study sections and to enhance ARVO's lobbying capabilities.
• Has run for many years a successful fellowship program for clinicians interested in Ocular inflammatory disease. Take two fellows/year and consistently fill the slots through the match.

Presently:
• Chief of the Laboratory of Immunology • Chief of the Office of Protocol Services, CC, NIH. Responsible for the administrative handling of the 1100 protocols on the NIH campus. Preparing a web-based protocol writing system (ProtoType) which will be used at NIH and linked to an adverse events reporting system as well as to the new clinical research information system (CRIS) at the NIH.
• Senior advisor to the Deputy Director of Intramural Research, NIH.

Stephen C. Pflugfelder, MD graduated from Colgate University summa cum laude and SUNY Upstate Medical University Syracuse where he was elected to AOA. He did his Ophthalmology residency at Baylor College of Medicine where he served as Chief Resident in 1984. He performed a Cornea fellowship at the Bascom Palmer Eye Institute of the University of Miami School of Medicine. He was appointed to the faculty of the Bascom Palmer Eye Institute in 1985 and was promoted to Professor in 1998. He joined the faculty of the Cullen Eye Institute of Baylor College of Medicine as a Professor and Director of the Ocular Surface Center in July 2000. He was awarded the James and Margaret Elkins Chair in Ophthalmology at Baylor College of Medicine in 2001. He has published over 160 peer-reviewed articles and over 45 book chapters and monographs, primarily in the field of cornea diseases and surgery. He served as a co-editor for "Dry Eye and Ocular Surface Disorders" a comprehensive textbook on the subject that was published in 2004. He was included in the last four editions of "Best Doctors in America". He received the American Academy of Ophthalmology Senior Achievement Award in 2000 and a Research to Prevent Blindness Senior Investigator Award in 2002.

He served as Chairman of the American Academy of Ophthalmology Lifelong Education for Ophthalmologists Committee and as a past member of the American Academy of Ophthalmology Preferred Practice Pattern Committee on Corneal and Ocular Surface diseases. He is on the Editorial Boards of the journals American Journal of Ophthalmology, Cornea, Investigative Ophthalmology and Visual Science and The Ocular Surface. His research interests include the role of inflammation in dry eye and corneal bioengineering.

Consultant or Advisory Board: Allergan, Bausch and Lomb
Speaker Bureau: Allergan, Bausch and Lomb, Inspire
Research Support: Allergan, Advanced Medical Optics, Inspire

Paul Sternberg Jr., MD is George W. Hale Professor and Chair, Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University School of Medicine.

Dr. Sternberg is a graduate of Harvard College and University of Chicago Pritzker School of Medicine. He completed his ophthalmology training at the Wilmer Eye Institute at Johns Hopkins. Following a vitreoretinal fellowship at Duke University Eye Center, he returned to Wilmer as Chief Resident for the 1984-85 academic year. In 1985, he joined the faculty at Emory University, where he rose to become the Thomas M. Aaberg Professor and Director of the Vitreoretinal Service. In 2003, he assumed the chairmanship at Vanderbilt.

Dr. Sternberg is certified by the American Board of Ophthalmology and is a member of the Macula Society, the Retina Society, the American Society of Retina Specialists, and the Club Jules Gonin. Dr. Sternberg has held numerous positions with the American Academy of Ophthalmology, including Secretary of Communications, and currently is a member of the Board of Trustees. In addition, he was recently elected to the Board of Trustees of the Association for Research in Vision and Ophthalmology (ARVO). He has been a member of the NIH Study Section on Retinal and Choroidal Diseases, chairing that panel from 1997-1998 and served on their Board of Scientific Councilors from 2004-2007.

Dr. Sternberg is the recipient of many awards and honors, including the American Academy of Ophthalmology Senior Honor Award, Vitreous Society Honor Award, the L.E. Brown Humanitarian Award from the Georgia Society of Ophthalmology, and the Heed Ophthalmic Foundation Award. He was named one of the Best Doctors in America, 1994 to 2007 and one of America's Top Doctors from 2003 to 2007. Dr. Sternberg received the Lew R. Wasserman Award of Merit from Research to Prevent Blindness in 1998 and the Sommer Prize for research in macular degeneration in 2007.

Dr. Sternberg's clinical and research interests focus on retinal diseases, with a particular emphasis on age-related macular degeneration. He oversees an active laboratory research program studying the pathogenesis of this condition. He has received funding support from the National Eye Institute, Foundation Fighting Blindness, Research to Prevent Blindness, and the Macula Society. In addition, he has participated in numerous clinical trials, sponsored both by NIH and industry.

Consultant or Advisory Board: Acucela, Genentech, Othera, Alcon
Research Support: Alcon, Othera

Fotis Topouzis, MD is an Assistant Professor of Ophthalmology at the Aristotle University of Thessaloniki (AUTH), Greece. Fotis Topouzis received his MD in Medicine from AUTH in 1986. He pursued residency training in Ophthalmology at the "Saint-Antoine" Hospital and National Center of Ophthalmology "Quinze Vingts" Hospital Paris, France from 1986 to 1990. In 1992 he received his Ph.D. in Psychophysics at the Democritus University of Thrace, Alexandroupolis, Greece. He completed his Fellowship in comprehensive ophthalmology and cornea at the National Center of Ophthalmology "Quinze Vingts" Hospital Paris, France as "Assistant Specialiste des Hopitaux de Paris" in 1993. He completed his Fellowship in glaucoma at the Jules Stein Eye Institute, Los Angeles, CA, USA in 1998. He joined the Department of Ophthalmology at the Aristotle University of Thessaloniki from 1998 to 2000 as University Associate. He has served at the Department of Ophthalmology, "Papageorgiou" hospital, Thessaloniki, as Consultant-Interim Director of the Department from 1999 to 2000. In 2001 he became Lecturer in Ophthalmology at the Aristotle University of Thessaloniki and he is the Head and Founder of the Laboratory of Research and Clinical Applications in Ophthalmology. In 2004 Dr Topouzis joined the newly established B' Department of Ophthalmology at the Aristotle University of Thessaloniki and in 2005 he became Assistant Professor in the same Department. Since November 2008 Professor Topouzis and the Laboratory of Research and Clinical Applications in Ophthalmology moved to a new and recently renovated larger space in the A' Department of Ophthalmology, AUTH, AHEPA Hospital, Thessaloniki.

Dr Topouzis has participated one visiting professorship: Jules Stein Eye Institute, Los Angeles, CA. He also served as an Assistant Professor at the Department of Ophthalmology, Democritus University of Thrace, Alexandroupolis, Greece. Dr. Topouzis has received the distinguished foreign resident Award from the College of Medicine of the Hospitals in Paris, Post -Doctoral Award from the Aristotle University of Thessaloniki, Greece and Shaffer International Fellowship Award from the Glaucoma Research Foundation, San Fransisco, CA.

Dr. Topouzis is member of the Executive Committee of the European Glaucoma Society (EGS) and Secretary of GlaucoGENE, a special interest group of the European Glaucoma Society. Dr. Topouzis serves four medical journal editorial boards and is a reviewer for seventeen medical journals. Dr Topouzis is especially interested in epidemiology and clinical and genetic research in ophthalmic diseases with particular focus in glaucoma and age related macular degeneration. He is Principal Investigator of two large population-based studies (Thessaloniki Eye Study, Eureye Study) and coordinator of the EGS GlaucoGENE project.

Consultant or Advisory Board: Pfizer, Merck
Speaker's Bureau: Pfizer, Alcon.
Research Support: Pfizer, Alcon, Heidelberg Engineering.

David T. Tse, MD is Professor of Ophthalmology in the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine in Miami, Florida. He holds the Dr. Nasser Ibrahim Al-Rashid Endowed Chair in Ophthalmic Plastic, Orbital Surgery and Oncology in the Department of Ophthalmology.

He received his medical degree from the University of Miami School of Medicine. His ophthalmology residency was completed at the University of Southern California in Los Angeles. Following residency, he completed ophthalmic plastic surgery fellowship training at the University of Iowa. He then joined the University of Iowa faculty in 1982 and stayed until 1986 when Dr. Edward Norton, founder of the Bascom Palmer Eye Institute, invited him to start the Ophthalmic Plastic Service in Miami.

Dr. Tse is the recipient of the El-Magrabi International Award, USC/Doheny Distinguished Alumnus Award, and the University of Miami Invention Recognition Award. He is recognized in Best Doctors in America and America's Top Doctors. He has had over 58 visiting professorships and delivered 8 named lectures. Dr. Tse has edited the Color Atlas of Ophthalmic Surgery: Oculoplastic Surgery and has authored more than 100 book chapters and peer-reviewed scientific articles. He is a member of several major ophthalmologic professional societies, including the American Ophthalmological Society. He is on the Editorial Board of Ophthalmic Plastic and Reconstructive Surgery Journal and currently serves as a Director of the American Board of Ophthalmology.

Dr. Tse's clinical interests include the full spectrum of lacrimal, eyelid and orbital reconstructive surgeries due to disease or injury, as well as aesthetic and rejuvenative surgeries. His clinical research efforts center on innovative ways to treat extensive skin cancers and lethal orbital malignancies and in translational research by integrating scientific discovery into clinical reality in terms of diagnostic and therapeutic approaches to oculoplastic and orbital diseases. Dr. Tse precepts an American Society of Ophthalmic Plastic and Reconstructive Surgery Inc. approved fellowship in oculoplastic and orbital surgery.

Patent: Integrated orbital expander
Research Support: Boston Scientific Corporation

Russell N. Van Gelder, MD, PhD, is a native of Manhattan. He received his BS, MD, and PhD (Neuroscience) degrees from Stanford University, where he also completed his medical internship. Dr. Van Gelder completed his ophthalmology residency at Barnes-Jewish Hospital in St. Louis, and his uveitis and medical retinal disease fellowship at Washington University and the Barnes Retina Institute. He served on the faculty of the departments of Ophthalmology and Visual Science, and Molecular Biology and Pharmacology at Washington University from 1999-2007, serving as the Bernard Becker Professor of Ophthalmology from 2006-2007. In 2008 he became Boyd K. Bucey Professor and Chair of the Department of Ophthalmology at the University of Washington School of Medicine, where he is also Director of the UW Medicine Eye Institute.

Dr. Van Gelder is a clinician-scientist with an active, NIH-funded laboratory investigating both the basis of non-visual photoreception in the eye and polymerase chain reaction diagnosis of ocular inflammatory disease. His clinical expertise is in uveitis and medical retinal disease.

Dr. Van Gelder is President of the American Uveitis Society. He is an Associate Editor of Ocular Immunology and Inflammation, and serves on the Editorial Boards of IOVS, the Journal of Biological Rhythms, and Molecular Vision in addition to the AJO. Dr. Van Gelder chairs the Commercial Relations committee of ARVO, and serves on the council of the American Academy of Ophthalmology. Among his honors have been the Society of Heed Fellows Fellowship, a NEI K08 Clinician-Scientist Award, the Research to Prevent Blindness Career Development Award, the inaugural Becker/AUPO/RPB Clinician Scientist Award, a NARSAD Young Investigator Award, the Culpeper Medical Scholar Award of the Rockefeller Brothers Foundation, and the Translational Scientist Award from the Burroughs-Wellcome Foundation.

Consultant or Advisory Board: Alcon, Novartis